Jazz Pharmaceuticals plc

NASDAQ:JAZZ   2:17:35 PM EDT
132.42
+0.68 (+0.52%)
Products

Jazz Pharmaceuticals Announces U.S. FDA Approval Of Xywav Oral Solution For Idiopathic Hypersomnia In Adults

Published: 08/12/2021 18:42 GMT
Jazz Pharmaceuticals plc (JAZZ) - Jazz Pharmaceuticals Announces U.S. FDA Approval of Xywav® (calcium, Magnesium, Potassium, and Sodium Oxybates) Oral Solution for Idiopathic Hypersomnia in Adults.
Jazz Pharmaceuticals Announces U.S. FDA Approval of Xywav® (calcium, Magnesium, Potassium, and Sodium Oxybates) Oral Solution for Idiopathic Hypersomnia in Adults.
Jazz Pharmaceuticals - Plans to Make Xywav Available to Patients With Idiopathic Hypersomnia Later This Year Following Rems Implementation.